The Quantum Leap program is intended to support outstanding translational research projects implementing state-of-the art technologies with very high potential impact in key areas of unmet needs within the biopharmaceutical industry. It is expected that the funded technologies should provide valuable opportunities for future collaborations and/or investment from key partners on a global scale.
This program is aimed at developing highly innovative technologies, platforms or tools with strong preliminary data showcasing high potential to drastically improve, facilitate and accelerate the process of discovery and development of drugs that prevent, treat or cure diseases in all major indications pursued by the biopharmaceutical industry.
Quantum Leap strategic initiative aims to bring disruptive technologies or platforms to a point where services and/or products generated by the platforms could be commercialized or further developed for use by the industry and/or the scientific community. The program strongly encourages public-private partnership for the development of technologies that create value for all partners involved.
The research agenda extends to all scientific and technical fields related to biopharmaceutical R&D and all disciplines that could provide new cutting-edge platforms to enhance and improve biopharmaceutical research productivity. The expectations are that the translational research projects will generate tangible results with catalytic effects on developing optimized approaches to the treatment of diseases by the biopharmaceutical industry.